Targeted attack on deadly blood cancer mutation begins human testing
NCT ID NCT06616636
Summary
This early-stage study is testing the safety and initial effectiveness of a new drug, rezatapopt, combined with an existing drug, azacitidine, for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The trial is specifically for patients whose cancer has a particular genetic change called a TP53Y220C mutation. Researchers will enroll about 24 participants to see how well the body handles the combination and if it helps control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.